{"id":954964,"date":"2026-04-27T16:05:28","date_gmt":"2026-04-27T20:05:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/"},"modified":"2026-04-27T16:05:28","modified_gmt":"2026-04-27T20:05:28","slug":"arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/","title":{"rendered":"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026<\/b><\/p>\n<p>SAN DIEGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nArcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7<sup>th<\/sup> and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026.<\/p>\n<p><b>Arcturus Therapeutics First Quarter 2026 Earnings Conference Call<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThursday, May 7, 2026, at 4:30 p.m. ET<\/p>\n<\/li>\n<li>\nDomestic: 1-800-579-2543<\/p>\n<\/li>\n<li>\nInternational: 1-785-424-1789<\/p>\n<\/li>\n<li>\nConference ID: ARCTURUS<\/p>\n<\/li>\n<li>\nWebcast: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1758350%26tp_key%3D71f69e33e5&amp;esheet=54523554&amp;newsitemid=20260427441828&amp;lan=en-US&amp;anchor=Link&amp;index=1&amp;md5=a71625ff68f189bc15c449e87765de1d\">Link<\/a><\/li>\n<\/ul>\n<p><b>About Arcturus<\/b><\/p>\n<p>\nFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u00ae mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE\u00ae, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus\u2019 pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus\u2019 versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus&#8217; technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ArcturusRx.com&amp;esheet=54523554&amp;newsitemid=20260427441828&amp;lan=en-US&amp;anchor=www.ArcturusRx.com&amp;index=2&amp;md5=ae98b2238544cdc8f76750ab2a05823f\">www.ArcturusRx.com<\/a>. Please connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Farcturusrx&amp;esheet=54523554&amp;newsitemid=20260427441828&amp;lan=en-US&amp;anchor=X&amp;index=3&amp;md5=6c833a0920bec2a95b5e8f0dad1750ad\">X<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farcturus-therapeutics&amp;esheet=54523554&amp;newsitemid=20260427441828&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=03da5613dda0dd80451ca58fe54900d3\">LinkedIn<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260427441828r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260427441828\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260427441828\/en\/<\/a><\/span><\/p>\n<p><b>Arcturus Therapeutics<br \/>\n<br \/><\/b>Public Relations &amp; Investor Relations<br \/>\n<br \/>Neda Safarzadeh<br \/>\n<br \/>VP, Head of IR\/PR\/Marketing<br \/>\n<br \/>(858) 900-2682<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:IR@ArcturusRx.com\">IR@ArcturusRx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Infectious Diseases Genetics General Health Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260427441828\/en\/2786251\/3\/arcturus-logo-blueback_%282%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026. Arcturus Therapeutics First Quarter 2026 Earnings Conference Call Thursday, May 7, 2026, at 4:30 p.m. ET Domestic: 1-800-579-2543 International: 1-785-424-1789 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-954964","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026. Arcturus Therapeutics First Quarter 2026 Earnings Conference Call Thursday, May 7, 2026, at 4:30 p.m. ET Domestic: 1-800-579-2543 International: 1-785-424-1789 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San &hellip; Continue reading &quot;Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T20:05:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260427441828r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026\",\"datePublished\":\"2026-04-27T20:05:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/\"},\"wordCount\":378,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260427441828r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/\",\"name\":\"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260427441828r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-04-27T20:05:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260427441828r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260427441828r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/","og_locale":"en_US","og_type":"article","og_title":"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 - Market Newsdesk","og_description":"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026. Arcturus Therapeutics First Quarter 2026 Earnings Conference Call Thursday, May 7, 2026, at 4:30 p.m. ET Domestic: 1-800-579-2543 International: 1-785-424-1789 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San &hellip; Continue reading \"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-27T20:05:28+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260427441828r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026","datePublished":"2026-04-27T20:05:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/"},"wordCount":378,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260427441828r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/","name":"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260427441828r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-04-27T20:05:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260427441828r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260427441828r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=954964"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954964\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=954964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=954964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=954964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}